What's new in the medical management of pediatric epilepsy?

Research output: Contribution to journalArticlepeer-review

Abstract

Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.

Original languageEnglish (US)
Pages (from-to)S30-S34
JournalCanadian Journal of Neurological Sciences
Volume39
Issue number6 SUPPL.6
DOIs
StatePublished - Nov 2012

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'What's new in the medical management of pediatric epilepsy?'. Together they form a unique fingerprint.

Cite this